Xiamen AmonMed Biotechnology Co., Ltd.
We launch professional POCT products with our leading technological strength.
We launch professional POCT products with our leading technological strength.

AmonMed Biotechnology was founded in 2014, is a national high-tech enterprise engaged in rare earth biomedical transformation technology. As a rare earth biomedical enterprise incubated by the Haixi Innovation Research Institute of the Chinese Academy of Sciences, AmonMed relying on the scientific research platform of the Chinese Academy of Sciences with strong R & D strength and technological strength. AmonMed has completed number of projects from national area or Chinese Academy of Science. At present, we have many patents, and have successfully developed a series of in vitro rare earth nano-fluorescent immunodiagnostic products with independent intellectual property rights. Among them, 27 products have passed the EU CE certification, 32 rare earth diagnostic kits and 2 rare earth nano-fluorescence immunoassay instruments have obtained the national medical device registration certificate.

Amonmed has committed to the research and development, production and sales of new miniaturized in vitro diagnostic detecting instruments and form a complete set of kits.

Honor
Patent

Pulse production device for nuclear magnetic resonance spectrometer

Patent

Pulse production device for nuclear magnetic resonance spectrometer

Patent

Pulse production device for nuclear magnetic resonance spectrometer

Patent
Patent
Patent
Development
2021
February

Passed the Paul-Ehrlich-Institut (PEI) Comparative evaluation of the sensitivities of SARS CoV-2 antigen rapid tests.

2020
July

Launched COVID-19 Test Kit (Ab & Ag), Colloidal Gold & Rare Earth Nano Fluorescence Immunochromatography.

2019
July

ISO 13485:2016


2018

August
Launched Class II 12 Products Registrated in NMPA

2017
February

Signed investment agreement with and obtained pre A funding from Cybernaut Investment Group, CE Mark of DOA Test Kits.



2016
June

China Innovatiion and Entrepreneurship Competition Finals Outstanding Projects,Selected as one of the first Fujian "Innovation 100" companies.












2015
June

Xiamen Zhongke Investment & Industrial Fund of Haixi Research Institute and CAS reached investment agreement, Registration of AmonMedCAS trademark.


2013
February

Relying on TIDE Medical, the TR-FIA POCT was launched in Munich, Germany


September

Selected for the 5th batch of Xiamen Double Hundred Plan Projects & AmonMed Founded